What's Happening?
Fifteen states have filed a lawsuit against the Department of Health and Human Services (HHS) challenging recent changes to the childhood immunization schedule. The lawsuit, led by Democratic states, targets the Centers for Disease Control and Prevention's
(CDC) decision to reduce the number of diseases targeted by routine childhood and adolescent immunizations from 17 to 11. This change follows a May 2025 decision to remove COVID-19 vaccines from the recommended list for healthy children and pregnant women. Vaccine manufacturers such as Pfizer, Moderna, Merck, GSK, and Sanofi are potentially affected by these changes. Despite the financial implications, legal experts suggest that these companies may choose not to support the states' legal challenge due to their current unpopularity. The American Academy of Pediatrics (AAP) had previously filed a case against similar changes, which included support from numerous public health organizations.
Why It's Important?
The changes to the immunization schedule could significantly impact vaccine manufacturers' sales, particularly for products like Merck's Gardasil, which has already seen reduced sales estimates. The legal challenge by the states highlights a broader conflict between public health policy and state governance, with potential implications for vaccine uptake and public health outcomes. The decision to exclude COVID-19 vaccines from the recommended list for children and pregnant women could lead to decreased vaccination rates, potentially affecting herd immunity and public health safety. The outcome of this legal battle could set a precedent for how vaccine schedules are determined and challenged in the future, influencing both public health policy and the pharmaceutical industry's strategic decisions.
What's Next?
The legal proceedings will continue as the states seek to have the new immunization schedule and changes to the Advisory Committee on Immunization Practices (ACIP) declared unlawful. The states argue that the appointment of 'unqualified ACIP members' and the bypassing of the committee in creating the new schedule were arbitrary and capricious. Public health organizations that supported the AAP's previous case are expected to file amicus briefs in support of the states' lawsuit. The outcome of this case could influence future vaccine policy and the role of federal agencies in public health decision-making.
